NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Now Rated “Hold” by Wall Street Brokerages

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have received an average rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $7.33.

A number of equities analysts have recently commented on the stock. Maxim Group set a $5.00 price target on shares of NeuroOne Medical Technologies and gave the stock a “buy” rating in a report on Friday, August 14th. Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st.

Insider Transactions at NeuroOne Medical Technologies

In related news, Director Mark Christianson sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the transaction, the director directly owned 20,692 shares of the company’s stock, valued at approximately $65,800.56. This trade represents a 32.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David J. Wambeke bought 33,333 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average price of $2.01 per share, with a total value of $66,999.33. Following the transaction, the insider directly owned 199,999 shares in the company, valued at $401,997.99. The trade was a 20.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 11.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Bard Associates Inc. bought a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter worth approximately $929,000. BlackRock Inc. bought a new position in shares of NeuroOne Medical Technologies during the 2nd quarter valued at $76,000. Susquehanna International Group LLP purchased a new position in NeuroOne Medical Technologies in the 2nd quarter worth $41,000. Finally, Legato Capital Management LLC purchased a new position in NeuroOne Medical Technologies in the 4th quarter worth $34,000. 16.07% of the stock is currently owned by institutional investors.

NeuroOne Medical Technologies Trading Down 0.7%

Shares of NMTC opened at $1.33 on Friday. NeuroOne Medical Technologies has a 12-month low of $1.30 and a 12-month high of $6.96. The company has a market cap of $12.12 million, a PE ratio of -1.40 and a beta of 0.65. The stock has a 50-day moving average price of $1.73 and a 200-day moving average price of $3.17.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.07). NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%.The company had revenue of $1.97 million during the quarter, compared to the consensus estimate of $2.17 million. As a group, analysts predict that NeuroOne Medical Technologies will post -0.39 earnings per share for the current year.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical technology company focused on developing, manufacturing and commercializing thin-film electrode technology for neurological applications. Its products are designed to support the recording, monitoring and stimulation of electrical activity in the brain and nervous system, with potential uses in the diagnosis and treatment of neurological disorders.

The company’s product portfolio includes the Evo family of electrode products, including devices used for stereoelectroencephalography and cortical monitoring.